Landos Biopharma Q4 EPS $(0.99) Misses $(0.91) Estimate, Cash Balance of $37.5M
Portfolio Pulse from Benzinga Newsdesk
Landos Biopharma (NASDAQ:LABP) reported a Q4 EPS loss of $(0.99), missing the consensus estimate of $(0.91) by 8.79%. However, this represents a 23.85% improvement over the $(1.30) loss per share from the same period last year. The company also reported a cash balance of $37.5M.
March 21, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Landos Biopharma reported a Q4 EPS loss of $(0.99), missing estimates but showing year-over-year improvement. Cash balance is $37.5M.
Missing the EPS estimate could negatively impact investor sentiment in the short term, leading to a potential decrease in stock price. However, the year-over-year improvement in losses and a solid cash balance might mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100